5-chloro-N-isopropyl-indolecarboxamide | 724783-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-N-isopropyl-indolecarboxamide
• 英文别名: 5-chloro-N-propan-2-yl-1H-indole-2-carboxamide
• CAS: 724783-47-5
• 化学式: C₁₂H₁₃ClN₂O
• 分子量: 236.701
• InChiKey: QGFQXLDTCJLJQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  tert-butyl N-[(3aR,4R,6aS)-2-[2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-yl]carbamate 、 异丙胺 以 二氯甲烷 为溶剂， 生成 5-chloro-N-isopropyl-indolecarboxamide
  参考文献：
  名称：

  2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

  摘要：

  提供了新颖的化合物，它们是糖原磷酸化酶抑制剂，可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病，如糖尿病及相关疾病（如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症），与糖尿病相关的微血管并发症（如视网膜病变、神经病变、肾病和伤口愈合延迟）、与糖尿病相关的大血管并发症（心血管疾病，如动脉粥样硬化、心脏功能异常、心肌缺血和中风），以及代谢综合征及其组成疾病，包括高血压、肥胖和脂质代谢异常（包括高三酸甘油酯血症、高胆固醇血症和低HDL），以及其他疾病，如非心脏缺血、感染和癌症。这些新颖的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐，其中W、R1、R2、X、Y和Z在此处被定义。

  公开号：

  US20060111413A1

文献信息

• Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
  申请人：——

  公开号：US20040142938A1

  公开（公告）日：2004-07-22

  Prodrugs of a glycogen phosphorylase inhibiting compounds are provided, said prodrug compounds having the formula I G(—O 2 CR′) m (—OH) n (—O 2 C(CH 2 ) p CH 3 ) q I wherein G is a C 3 to C 5 branched or straight carbon chain and (—O 2 CR′), (—OH) and (—O 2 C(CH 2 ) p CH 3 ) are attached to any available carbon atom along G; m is an integer from 1 to 4; n is an integer from 0 to 3; p is an integer from 0 to 16; q an integer from 0 to 3; where the sum of m, n and q is 3 or 4; and —O 2 CR′ is a fragment of a compound of formula 1 wherein W, X, Y, Z, R 1 and R 2 are as defined herein. Further provided are pharmaceutical compositions and methods for treating diabetes and related diseases employing compounds above, either alone or in combination with another therapeutic agent.

  提供了一种糖原磷酸化酶抑制化合物的前药，所述前药化合物具有以下式I G(—O 2 CR′) m (—OH) n (—O 2 C(CH 2 ) p CH 3 ) q I 其中G是C 3 到C 5 支链或直链碳链，(—O 2 CR′)、(—OH)和(—O 2 C(CH 2 ) p CH 3 )连接到G上的任何可用碳原子上； m是从1到4的整数； n是从0到3的整数； p是从0到16的整数； q是从0到3的整数；其中m、n和q的总和为3或4；以及 —O 2 CR′是具有以下式的化合物的片段 1 其中W、X、Y、Z、R 1 和R 2 如本文所定义。 还提供了使用上述化合物治疗糖尿病和相关疾病的药物组合物和方法，可以单独使用或与另一种治疗剂联合使用。
• Lactam glycogen phosphorylase inhibitors and method of use
  申请人：——

  公开号：US20040002495A1

  公开（公告）日：2004-01-01

  A compound of formula I 1 wherein W is a bicyclic hetroaryl of the structure 2 X is —O—, —S—, —SO 2 —, —CHR 5 —, —CHR 5 O—, —CHR 5 S—, —CHR 5 SO 2 —, —CHR 5 CO— or —CH 2 CHR 5 —; Y is a bond or —CHR 6 —; Z is an aryl or heteroaryl group of the following structure: 3 A is —CH— or —N—; B is —O— or —S—; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as described herein. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.

  公式I的化合物 其中 W是具有结构的双环杂芳基 X是—O—，—S—，—SO 2 —，—CHR 5 —，—CHR 5 O—，—CHR 5 S—，—CHR 5 SO 2 —，—CHR 5 CO—或—CH 2 CHR 5 —; Y是一个键或—CHR 6 —; Z是以下结构的芳基或杂芳基团： A是—CH—或—N—; B是—O—或—S—; 和 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 和R 8 如本文所述。 此外，提供了一种治疗糖尿病和相关疾病的方法，该方法使用上述化合物的糖原磷酸化酶抑制剂量，可以单独使用或与另一种治疗剂联合使用。
• [EN] INDOLE DERIVATIVES FOR USE IN MEDICINE<br/>[FR] DÉRIVÉS INDOLÉS DESTINÉS À ÊTRE UTILISÉS DANS LE DOMAINE DE LA MÉDECINE
  申请人：IOMET PHARMA LTD

  公开号：WO2015150097A1

  公开（公告）日：2015-10-08

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  提供了一种色氨酸2,3-双加氧酶（TDO）和/或吲哚酮-2,3-双加氧酶（IDO）抑制剂化合物，用于医学，该化合物包括以下结构式：其中X1、X2、X3、X4和X5可以相同或不同，并且每个独立地选择自C、N和O；每个有点线的原子可以独立地具有双键或单键，前提是保持每个原子的价；每个R1、R2、R3、R4、R5和R7可以存在或不存在，并且可以相同或不同，并且选择自H和取代或未取代的有机基团，前提是存在这样的R基团的数量使得X1、X2、X3、X4和X5的价被保持；可以存在一个或两个R6基团，并且选择自H和取代或未取代的有机基团，前提是存在这样的R6基团的数量使得它们附着的碳原子的价被保持，并且前提是至少有一个R6是包含一个与氧原子双键的原子的有机基团（优选为一个羰基基团或一个磺酰基基团），在其中与氧原子双键的原子也与一个杂原子键合。
• INDOLE DERIVATIVES FOR USE IN MEDICINE
  申请人：IOMet Pharma Ltd.

  公开号：US20190084933A1

  公开（公告）日：2019-03-21

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 1 , X 2 , X 3 , X 4 , and X 5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom arc maintained; each R 1 , R 2 , R 3 , R 4 , and R 7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 1 , X 2 , X 3 , X 4 , and X 5 are maintained; one or two R 6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R 6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R 6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R 6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  提供一种色氨酸-2,3-双加氧酶（TDO）和/或吲哚胺-2,3-双加氧酶（IDO）抑制剂化合物，用于医学，该化合物包括以下式子：其中X1、X2、X3、X4和X5可以相同或不同，并且每个独立地选择自C、N和O；每个有点线的原子可以独立地具有双键或单键，前提是每个原子的价被保持；每个R1、R2、R3、R4和R7可以存在或不存在，可以相同或不同，并且选择自H和取代或未取代的有机基团，前提是存在的这些R基团的数量使得X1、X2、X3、X4和X5的价被保持；可以存在一或两个R6基团，选择自H和取代或未取代的有机基团，前提是存在的这些R6基团的数量使得它们附着的碳原子的价被保持，并且至少有一个R6是包含一个双键连接到α-、β-或γ-位置的氧原子（优选为羰基基团或磺酰基团）的有机基团，并且其中双键连接到氧原子的原子也与杂原子相结合。
• Indole derivatives for use in medicine
  申请人：IOmet Pharma Ltd.

  公开号：US10167257B2

  公开（公告）日：2019-01-01

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  本发明提供了一种用于医药的色氨酸-2,3-二氧化酶（TDO）和/或吲哚胺-2,3-二氧化酶（IDO）抑制剂化合物，该化合物包括下式：其中 X1、X2、X3、X4 和 X5 可以相同或不同，且各自独立地选自 C、N 和 O；每个带有虚线的原子可以独立地具有双键或单键，前提是每个原子上的价保持不变；每个 R1、R2、R3、R4、R5 和 R7 可以存在或不存在，可以相同或不同，并且可以选自 H 和取代或未取代的有机基团，条件是存在的此类 R 基团的数目使得 X1、X2、X3、X4 和 X5 的化合价保持不变；可存在一个或两个 R6 基团，它们选自 H 和一个取代或未取代的有机基团，条件是所存在的 R6 基团的数目必须保证它们所连接的碳原子的价保持不变、且至少有一个 R6 是有机基团，该有机基团包含一个与氧原子（最好是羰基或磺酰基）在与 R6 所连接的碳原子的 α-、β- 或 γ- 位置上双键结合的原子，其中与氧原子双键结合的原子还与杂原子结合。